Emergent BioSolutions (NYSE:EBS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. Benchmark lifted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th.

Emergent BioSolutions Stock Up 3.1 %

Shares of NYSE EBS opened at $10.19 on Tuesday. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The firm has a market cap of $551.82 million, a price-to-earnings ratio of -2.48 and a beta of 1.60. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock’s 50-day simple moving average is $9.27 and its 200-day simple moving average is $9.24.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $293.80 million for the quarter, compared to analyst estimates of $328.72 million. During the same period in the previous year, the company earned ($1.44) earnings per share. As a group, equities analysts anticipate that Emergent BioSolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Emergent BioSolutions

Several hedge funds and other institutional investors have recently bought and sold shares of EBS. American Century Companies Inc. increased its holdings in Emergent BioSolutions by 240.9% in the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after buying an additional 623,201 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in shares of Emergent BioSolutions during the second quarter valued at approximately $93,000. Hsbc Holdings PLC grew its holdings in shares of Emergent BioSolutions by 36.1% during the second quarter. Hsbc Holdings PLC now owns 87,679 shares of the biopharmaceutical company’s stock valued at $614,000 after purchasing an additional 23,250 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Emergent BioSolutions by 218.0% during the second quarter. XTX Topco Ltd now owns 62,764 shares of the biopharmaceutical company’s stock valued at $428,000 after purchasing an additional 43,028 shares during the last quarter. Finally, Morse Asset Management Inc bought a new position in shares of Emergent BioSolutions during the second quarter valued at approximately $97,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.